Skip to main content
. 2006 Nov 28;4:7. doi: 10.1186/1476-8518-4-7

Table 1.

Study Population Characteristics

Patient No. MHC Class I Before HAART Intensification Before First Treatment Interruption (TI)
A B C CD4 Cell Count (cells/mm3) CD4 Cell % CD4 Cell Count (cells/mm3) CD4 Cell %

14001 A2/A26 B18/B39 Cw7/Cw12 990 30 1120 33
14002 A2/A1 B60/B51 Cw3/Cw14 330 25 280 25
14003 A1/A3 B7/B8 Cw7/- 650 25 590 27
14004 A2/A3 B38/B44 Cw5/Cw12 400 19 370 22
14005 A3/A69 B35/B44 Cw12/Cw7 230 21 510 27
14006 A1/- B8/B57 Cw6/Cw7 440 23 410 24
14007 A36/A68 B7/B53 Cw4/Cw7 370 16 320 17
14008 A1/A68 B8/B60 Cw3/Cw7 350 14 720 19
14009 A3/A29 B35/B44 Cw4/Cw16 710 37 800 38
14010 A2/A66 B7/B14 Cw7/Cw8 290 24 370 37
Median (range) 476 (230–990) 23.4 (16–37) 549 (280–1120) 25.9 (17–38)